| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
B026 exhibits antiproliferative action against cancer cell lines (0-5 μM; 12 hours) [1]. B026 (0–5 μM; 6 hours; MV-4–11 cells) suppresses the expression of H3K27Ac [1]. B026 (0-5 μM; 12 hours; MV-4-11 cells) acts on the cellular p300 protein and, in a dose-dependent way, raises the protein's thermal stability [1]. The expression of MYC, a crucial oncogenic transcription factor controlled by a super-enhancer region containing p300/CBP, is decreased by B026 (0-1 μM; 24 hours; MV-4-11 cells) [1].
|
|---|---|
| ln Vivo |
B026 (1-3 mg/kg; IV and PO; 0-24 hours; male SD rats) has good oral exposure (AUC=3.71 μM·h) and good oral bioavailability (F=56%) in rats, but low clearance (13.4 mL/min/kg) [1]. In a dose-dependent manner, B026 (50-100 mg/kg; oral; daily for 28 days; balb/c female mice) inhibits the growth of tumors [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Maver-1, MV-4-11, K562, Kasumi-1, LnCaP-FGC and 22Rv1 Cell Tested Concentrations: 0-5 μM Incubation Duration: 12 hrs (hours) Experimental Results: Inhibition of cell growth, IC50 value 2.6, 4.2, 4.4, 9.8, 40.5 and 104.4 nM for Maver-1, MV-4-11, 22Rv1, LnCaP-FGC, Kasumi-1 and K562 cells, respectively. Western Blot Analysis [1] Cell Types: MV-4-11 cells Tested Concentrations: 0, 0.313, 0.625, 1.25, 2.5 and 5 μM Incubation Duration: 6 hrs (hours) Experimental Results: The expression of H3K27Ac diminished in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Balb/c female mice with MV-4-11 xenografts [1]
Doses: 50 and 100 mg/kg Route of Administration: Oral; Route of Administration: Oral. one time/day for 28 days. Experimental Results: Inhibition of tumor growth, TGI was 75.0% at 50 mg/kg and 85.7% at 100 mg/kg. Animal/Disease Models: Male SD rat [1] Doses: 1 and 3 mg/kg Route of Administration: intravenous (iv) (iv)injection and oral administration; 0.25, 0.5, 1, 2, 4, 8 and 24 hrs (hrs (hours)) Experimental Results: 1.19 intravenous (iv) (iv)injection (1 mg/ kg) Oral (3 mg/kg) T1/2 (h) 1.5 1.02 Tmax (h) 0.83 Cmax (μM) 1.12 AUClast (μM·h) 2.22 3.71 Vdss (L/kg) 1.5 CL_obs (mL/min/kg) 13.4 PPB % 98.2 F % 56 |
| References |
| Molecular Formula |
C27H23F4N5O4
|
|---|---|
| Molecular Weight |
557.496239900589
|
| Exact Mass |
557.168
|
| CAS # |
2379416-48-3
|
| PubChem CID |
146205579
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
40
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CN1C=C(C=N1)C2=CC3=C(C=C2)[C@@]4(CC3)C(=O)N(C(=O)N4)CC(=O)N5CC6=C(C=CC(=C6)F)OC[C@H]5C(F)(F)F
|
| InChi Key |
VDEZYUOBIXKTHI-NVQXNPDNSA-N
|
| InChi Code |
InChI=1S/C27H23F4N5O4/c1-34-11-18(10-32-34)15-2-4-20-16(8-15)6-7-26(20)24(38)36(25(39)33-26)13-23(37)35-12-17-9-19(28)3-5-21(17)40-14-22(35)27(29,30)31/h2-5,8-11,22H,6-7,12-14H2,1H3,(H,33,39)/t22-,26-/m0/s1
|
| Chemical Name |
(3S)-3'-[2-[(3S)-7-fluoro-3-(trifluoromethyl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-2-oxoethyl]-6-(1-methylpyrazol-4-yl)spiro[1,2-dihydroindene-3,5'-imidazolidine]-2',4'-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7937 mL | 8.9686 mL | 17.9372 mL | |
| 5 mM | 0.3587 mL | 1.7937 mL | 3.5874 mL | |
| 10 mM | 0.1794 mL | 0.8969 mL | 1.7937 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
